Does COVID-19 infection increase the risk of pulmonary embolism in ambulatory patients with deep vein thrombosis

Abstract

Objectives

Coronavirus disease 2019 (COVID-19) can lead to systemic coagulation activation and thrombotic complications including venous thromboembolism. This study compares the development of pulmonary embolism, post-thrombotic syndrome, and clinical outcomes of COVID-19 and non-COVID-19 patients with deep vein thrombosis (DVT).

Methods

One hundred and eight patients diagnosed with acute deep vein thrombosis (DVT) between June 2020 and February 2021 in our institution were included in this retrospective study. Thirty-nine patients had been previously diagnosed with COVID-19 and specified as the COVID-19 group. Sixty-nine patients did not have COVID-19 and specified as the non-COVID-19 group. Mean ages of both groups were 64.3 ± 15.8 and 60.1 ± 19.7 years, respectively (p = .37).

Results

The median duration from the onset of the COVID-19 to diagnosis of DVT was 22 (2–120) days in the COVID-19 group. The patients of two groups were mostly treated outpatient at rates of 94.9% vs 94.2%, respectively (p = .88). Pulmonary embolism was seen in six patients (15.4%) in the COVID-19 group and in three patients (4.3%) in the non-COVID-19 group (p = .04). Kaplan–Meir curves showed that patients with COVİD-19 had significantly higher pulmonary embolism than those without COVID-19 (p = .015). The recurrence rate of DVT was 2.6% in the COVID-19 group (n = 1), and 4.3% in the non-COVID-19 group (n = 3), indicating no statistically significant difference (p = .63). Mortality was seen in six patients (15.4%) in the COVİD-19 group, and in seven patients (10.1%) in the non-COVID-19 group. According to the Kaplan–Meir method, 10 months survival rates were 73.9 ± 10% in the COVID-19 group, and 66.3 ± 12.8% in the non-COVID-19 group with no statistical significance (p = .218).

Conclusions

Our data draw attention to the fact that deep vein thrombosis should not be considered a safe and self-limited condition. Efficient preventive measures such as mobilization and prophylactic drug use should be considered to prevent DVT during the management of COVID-19.

Keywords

COVID-19 SARS-CoV-2 deep vein thrombosis

Get full access to this article

View all access options for this article.

References

Byrnes

Wolberg

. New findings on venous thrombogenesis. Hamostaseologie 2017; 37: 25–35.

Ashrani

Heit

. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis 2009; 28: 465–476.

Bulger

Jacobs

Patel

. Epidemiology of acute deep vein thrombosis. Tech Vasc Interv Radiol 2004; 7: 50–54.

Sun

Wang

, et al. Covid-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med 2020; 26: 483–495.

Lipstein

Swerdlow

Finelli

. Defining the epidemiology of Covid-19—studies needed. N Engl J Med 2020; 382: 1194–1196.

Bikdeli

Madhavan

Jimenez

, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020; 75: 2950–2973.

Arnoldussen

Wittens

. An imaging approach to deep vein thrombosis and the lower extremity thrombosis classification. Phlebology 2012; 27: 143–148.

National Health Commission of the People’s Republic of China . Chinese Management Guideline for COVID-19, Version 6.0. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf. Published 19 February 19 2020.

Silverstein

Heit

Mohr

, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158(6): 585–593.

10.

Spencer

Emery

Lessard

, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21(7): 722–727.

11.

Kesieme

Jebbin

, et al. Deep vein thrombosis: a clinical review. J Blood Med 2011; 2: 59–69.

12.

Mackman

Antoniak

Wolberg

, et al. Coagulation abnormalities and thrombosis in patients infected with SARS-CoV 2 and other pandemic viruses. Arterioscler Thromb Vasc Biol 2020; 40(9): 2033–2044.

13.

Wang

Chen

Liu

, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol 2020; 7(5): e362–e363.

14.

Cui

Chen

, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia, J Thromb Haemost 2020; 18(6): 1421–1424.

15.

Giorgi-Pierfranceschi

Paoletti

Pan

, et al. Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study. Intern Emerg Med 2020; 15(8): 1425–1433.

16.

Righini

Paris

Le Gal

, et al. Clinical relevance of distal deep vein thrombosis. Review of literature data, Thromb Haemost 2006; 95: 56–64.

17.

Jiménez

García-Sanchez

Rali

, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: A systematic review and meta-analysis. Chest 2021; 159(3): 1182–1196.

18.

Prandoni

Lensing

Buller

, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441–445.

19.

Büller

Gent

Gallus

, et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657–662.

20.

Agnelli

Buller

Cohen

, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699–708.

21.

Bauersachs

Berkowitz

Brenner

, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–2510.

22.

Watson

Broderick

Armon

. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev 2016; 11: CD002783.

23.

Enden

Haig

Kløw

, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379(9810): 31–38.

24.

Pinney

Giustino

Halperin

, et al .

Coronavirus historical perspective, disease mechanisms, and clinical outcomes: JACC focus seminar

J Am Coll Cardiol 2020; 76(17): 1999–2010.

25.

Steinberg

Goldenberg

Lee

. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods. Antivir Res 2012; 93: 2–15.

26.

Zhang

Holmes

. A genomic perspective on the origin and emergence of SARS-CoV. Cell 2020; 181: 223–227.

27.

Zhai

Chen

, et al. Prevention treatment of VTE associated with COVID-19 infection consensus statement group. Thromb Haemost 2020; 120: 937–948.

28.

Paranjpe

Fuster

Lala

, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 2020; 76: 122–124.